EJPMR, 2026, 13(3), 385-392 **Review Article** **Impact Factor: 8.158**

EUROPEAN JOURNAL OF PHARMACEUTICAL AND MEDICAL RESEARCH

www.ejpmr.com

ISSN (O): 2394-3211
ISSN (P): 3051-2573
Coden USA: EJPMAG

ULTRA-PERFORMANCE LIQUID CHROMATOGRAPHY (UPLC) BASED ANALYTICAL METHOD DEVELOPMENT AND VALIDATION FOR PHARMACEUTICAL DOSAGE FORMS: A COMPREHENSIVE REVIEW

Pinky Soni*, Aparna Arora, Anju Goyal

Department of Pharmaceutical Quality Assurance Bhupal Nobles' College of Pharmacy Bhupal Nobles' University, Udaipur (Rajasthan) 313001.

***Corresponding Author: Pinky Soni**
Department of Pharmaceutical Quality Assurance Bhupal Nobles' College of Pharmacy Bhupal Nobles' University, Udaipur (Rajasthan) 313001. **DOI:** https://doi.org/10.5281/zenodo.18875259

How to cite this Article: Pinky Soni*, Aparna Arora, Anju Goyal. (2026). Ultra-Performance Liquid Chromatography (Uplc) Based Analytical Method Development And Validation For Pharmaceutical Dosage Forms: A Comprehensive Review. European Journal of Pharmaceutical and Medical Research, 13(3), 385–392.

Article Received on 04/02/2026 **Article Revised on 25/02/2026** **Article Published on 01/03/2026**

ABSTRACT
Liquid chromatographic techniques remain central to pharmaceutical quality evaluation, with High-Performance Liquid Chromatography (HPLC) historically serving as the primary analytical platform. Technological refinement has led to Ultra-Performance Liquid Chromatography (UPLC), which preserves HPLC separation principles while significantly improving efficiency, resolution, and analytical speed. UPLC is increasingly adopted for assay determination, impurity profiling, and stability-indicating analysis of pharmaceutical dosage forms. Method development and validation strategies for UPLC remain grounded in regulatory frameworks originally established for HPLC but require refined optimization due to high-pressure operation and sub-2 µm particle columns. This review presents foundational HPLC concepts, the scientific evolution toward UPLC, systematic method development workflows, validation requirements, dosage form applications, comparative performance, and future directions in pharmaceutical analysis.

KEYWORDS: Ultra-Performance Liquid Chromatography (UPLC), High-Performance Liquid Chromatography (HPLC), Analytical Method Development, Method Validation, Pharmaceutical Dosage Forms, Chromatographic Analysis, Stability-Indicating Methods.

1. INTRODUCTION
Analytical science plays a foundational role in the pharmaceutical sector because every stage of drug development and manufacturing depends on reliable measurement of chemical entities. From early drug discovery to final product release, analytical methods are required to establish identity, strength, purity, quality, and stability of drug substances and finished dosage forms. Among the available analytical approaches, liquid chromatographic techniques have gained exceptional importance due to their selectivity, reproducibility, and broad applicability across chemically diverse compounds. High-Performance Liquid Chromatography (HPLC) has therefore remained one of the most widely adopted analytical tools in pharmaceutical laboratories for several decades.[1]

HPLC became dominant because it supports accurate quantification of active pharmaceutical ingredients (APIs), related substances, and degradation products in complex matrices such as tablets, capsules, injectables, and biological fluids. Its compatibility with multiple detection systems — including ultraviolet (UV), photodiode array (PDA), fluorescence, and mass spectrometry — further increased its analytical versatility. Regulatory agencies worldwide recognize HPLC as a reference technique for assay and impurity testing, and many pharmacopeial monographs are built around HPLC procedures. As a result, method development and validation frameworks in pharmaceutical analysis were historically shaped around HPLC performance characteristics.[2]

Advances in particle engineering, instrument pressure tolerance, and system design led to the development of Ultra-Performance Liquid Chromatography (UPLC), also commonly referred to as UHPLC in some literature. This technique applies the same chromatographic separation principles as HPLC but uses columns packed with sub-2-micron particles and systems capable of operating at significantly higher pressures. According to chromatographic theory, decreasing particle size improves separation efficiency and reduces band broadening when extra-column dispersion is minimized. UPLC systems are specifically engineered to take advantage of these theoretical benefits in practical analytical workflows.[3]

The introduction of UPLC enabled analysts to achieve faster separations with sharper peaks, improved resolution, and enhanced detection sensitivity while reducing solvent consumption. These characteristics are particularly valuable in pharmaceutical dosage form analysis, where large numbers of samples must be processed under validated conditions. High throughput, reduced cycle time, and improved impurity resolution make UPLC attractive for both research and quality control applications. However, because UPLC operates under tighter tolerances and higher pressures, method development requires more structured optimization compared with conventional HPLC methods.[4]

It is important to emphasize that UPLC does not replace the scientific foundation of HPLC; rather, it represents a technological refinement built upon it. Core chromatographic variables — including stationary phase chemistry, mobile phase composition, pH control, temperature, and flow dynamics — remain central in both techniques. Similarly, regulatory expectations for analytical method validation are shared between HPLC and UPLC. International guidelines describing specificity, linearity, accuracy, precision, detection limits, and robustness apply equally to both approaches. Therefore, analysts transitioning from HPLC to UPLC benefit from strong conceptual continuity while adapting to enhanced system performance.[5]

2. HPLC Fundament.als Supporting Modern Method Development

HPLC operates through differential interaction of analytes between a mobile liquid phase and a stationary phase packed inside a column. Separation occurs because compounds exhibit different affinities toward these phases depending on polarity, ionization state, and molecular structure. Reversed-phase chromatography using hydrophobic stationary phases remains dominant in pharmaceutical analysis due to its broad applicability.[6]

A standard HPLC system includes solvent delivery modules, degassing units, precision pumps, injectors, analytical columns, detectors, and computerized data handling systems. Method development traditionally involves optimization of solvent composition, buffer strength, pH, temperature, and flow rate to achieve suitable resolution and peak shape. These same variables remain central in UPLC, although their operational ranges are narrower and more sensitive.[7]

Validation principles widely used today — specificity, linearity, precision, accuracy, detection limits, and robustness — were originally formalized around HPLC methods and remain directly applicable to UPLC procedures.[8]



Figure 1: Basic Components of an HPLC Analytical System.

3. Scientific Evolution from HPLC to UPLC

UPLC technology emerged from efforts to improve chromatographic efficiency by reducing stationary phase particle size. Chromatographic theory demonstrates that smaller particles lower plate height and increase separation efficiency when system dispersion is minimized. This allows faster separations without sacrificing resolution.[9]

Traditional HPLC columns typically use particles in the 3–5 µm range, whereas UPLC columns employ particles below 2 µm and operate at substantially higher pressures. The combined effect of particle size reduction and pressure tolerance enables shorter columns, sharper peaks, and shorter run times.[10]

Direct method transfer from HPLC to UPLC is rarely straightforward because dwell volume, gradient delay, and injection effects differ between systems. Structured translation and re-optimization are therefore recommended to preserve selectivity and robustness.[11]

Table 1: Comparison between HPLC and UPLC Systems.

Parameter	HPLC	UPLC
Particle size	3–5 µm	< 2 µm
Operating pressure	Up to ~400 bar	Up to ~1000 bar or higher
Column length	Longer	Shorter
Run time	Moderate to long	Short
Resolution	Good	Very high
Solvent consumption	Higher	Lower
Sensitivity	Moderate	Higher
Sample throughput	Moderate	High
Detector compatibility	UV, PDA, MS	PDA, MS/MS, HRMS
Application trend	Established	Advanced / high-throughput



Figure 2: UPLC Instrumentation and Column Considerations.

4. UPLC Instrumentation and Column Considerations

UPLC systems are engineered to minimize extra-column dispersion while tolerating elevated pressures. Pumps must deliver highly precise low-volume flow, and auto samplers must support reproducible micro-volume injections. Detector flow cells are correspondingly reduced in volume to maintain peak integrity.[12]

Column construction is critical in UPLC. Hybrid particle technologies and mechanically reinforced packing materials are commonly used to withstand pressure stress. Column lengths are generally shorter than in HPLC, contributing to faster analysis without compromising resolution.[13]

UPLC platforms are frequently coupled with photodiode array and mass spectrometric detectors, which expand their usefulness in impurity identification and bioanalytical measurement.[14]



Figure 3: Instrumental Configuration of a UPLC System.

5. Structured Strategy for UPLC Method Development

Successful UPLC method development begins with defining the analytical objective and understanding analyte physicochemical properties. Parameters such as solubility, pKa, polarity, and UV absorption guide early selection of stationary phase and mobile phase conditions.[15]

Initial screening typically uses reversed-phase columns with buffered aqueous phases and either acetonitrile or methanol as organic modifier. Gradient elution is often advantageous for multi-component formulations because it improves separation across a broad polarity range.[16]

Because UPLC columns are small and highly efficient, injection volume and sample solvent strength must be controlled carefully to avoid peak distortion. Temperature and flow rate adjustments are used to fine-tune selectivity and backpressure.[17]

Quality by Design and Design of Experiments approaches are increasingly incorporated to identify critical method parameters and establish a design space that supports robustness.[18]



Figure 4: Stepwise Workflow for UPLC Analytical Method Development.

Table 2: Key Parameters in UPLC Method Development.

Parameter	Considerations
Column chemistry	C18, C8, Phenyl, Polar embedded
Particle type	BEH, hybrid silica
Mobile phase	Buffer + organic modifier
pH	Based on analyte pKa
Organic solvent	Acetonitrile / Methanol
Flow rate	Lower than HPLC but high velocity
Temperature	30–60°C optimization
Injection volume	Very small (≤ 2 µL typical)
Detection wavelength	Based on UV maxima
Elution mode	Gradient preferred for mixtures

6. Method Development for Pharmaceutical Dosage Forms

Dosage form analysis introduces matrix complexity because excipients and additives may interfere with chromatographic detection. Appropriate sample preparation — including dilution, extraction, and filtration — is therefore essential.[19]

UPLC methods are particularly well suited for combination products because high efficiency enables separation of multiple active ingredients within short run times. This supports high-throughput quality control operations.[20]

For stability-indicating methods, forced degradation studies are performed under stress conditions to demonstrate separation between the active drug and degradation products. Peak purity assessment strengthens specificity claims.[21]



Figure 5: Schematic Workflow for Stability Indicating Method Development.

7. Validation of UPLC Methods

UPLC method validation follows internationally recognized frameworks and mirrors HPLC validation principles. The goal is to demonstrate that the analytical method is suitable for its intended use.[22]

Specificity confirms absence of interference, linearity demonstrates proportional response, accuracy evaluates recovery, and precision measures repeatability and intermediate precision.[23]

Detection and quantification limits are estimated statistically, and robustness studies evaluate the impact of small deliberate method changes. Robustness is especially important in UPLC due to higher sensitivity to parameter variation.[24]

Table 3: UPLC Method Validation Parameters (ICH Based).

Validation Parameter	Purpose
Specificity	No interference at analyte peak
Linearity	Response proportional to concentration
Accuracy	% Recovery close to 100%
Precision	Repeatability & intermediate precision
LOD	Lowest detectable amount
LOQ	Lowest quantifiable amount
Robustness	Stability under small changes
System suitability	Performance before analysis

Table 4: Typical System Suitability Criteria in UPLC.

Parameter	Typical Limit
%RSD (peak area)	≤ 2%
Tailing factor	≤ 2
Theoretical plates	> 2000
Resolution	> 2
Retention time RSD	≤ 1%



Figure 6: Stepwise Workflow for Validation of UPLC Analytical Methods.

8. Comparative Evaluation of HPLC and UPLC

Comparative investigations show that UPLC generally delivers faster separations, higher peak capacity, and lower solvent consumption compared with HPLC. These advantages align with efficiency and sustainability goals in pharmaceutical laboratories.[25]

However, UPLC requires greater capital investment and careful maintenance. Sample cleanliness and filtration are more critical due to small particle columns and high pressure operation.[26]

Both techniques remain acceptable within regulatory frameworks when properly validated, and method selection should be guided by analytical requirements and laboratory capability.[27]

9. Analytical Procedure Development and Validation under ICH Q2(R2) and Q14

Recent regulatory developments have significantly modernised the framework governing analytical procedure development and validation. The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use introduced ICH Q14 (2023) to provide harmonised guidance on analytical procedure development, complementing the revised ICH Q2(R2) guideline for validation.[28] While earlier guidance (Q2(R1)) focused primarily on validation characteristics such as accuracy, precision, specificity, linearity, range, LOD, LOQ, and robustness, it lacked a structured approach to method development and lifecycle management.[29]

ICH Q14 establishes the concept of the Analytical Target Profile (ATP), which defines the intended purpose and required performance of an analytical method. Development activities are expected to follow a science- and risk-based approach, incorporating identification of Critical Method Parameters (CMPs) and, where appropriate, design of experiments to define a Method Operable Design Region. This approach aligns analytical development with quality risk management principles and pharmaceutical quality systems.[30]

ICH Q2(R2), adopted concurrently, retains classical validation parameters but expands applicability to modern analytical technologies, including multivariate and advanced chromatographic methods such as UPLC. Importantly, validation under Q2(R2) is intended to confirm that the developed method consistently meets the predefined ATP.[31] The integration of Q14 and Q2(R2) introduces a lifecycle perspective, where analytical procedures are continuously monitored and managed post-approval, enabling scientifically justified changes while maintaining regulatory compliance.[32]

Together, these guidelines represent a shift from a validation-centric model to a comprehensive lifecycle-based framework for analytical science in pharmaceutical development.

10. Challenges and Future Trends

Despite its clear analytical advantages, UPLC implementation presents several practical and technical challenges that laboratories must address. One of the primary limitations is the higher capital and maintenance cost of UPLC instrumentation compared with conventional HPLC systems. The requirement for high-pressure tolerance, specialized low-dispersion components and precision column packing increases system expense and service sensitivity. In addition, sub-2 µm particle columns are more susceptible to blockage and performance loss if sample preparation and filtration are not strictly controlled. This places greater emphasis on sample cleanup and system suitability practices.[33]

From a regulatory perspective, increased method sensitivity in UPLC sometimes reveals trace impurities that were previously undetected, creating additional evaluation and qualification requirements. While scientifically beneficial, this can complicate impurity profiling and specification setting during product development and lifecycle management. Robust method design and risk-based validation approaches are therefore increasingly recommended.[34]

Future trends indicate that UPLC will continue to evolve toward greater integration with automated and data-driven analytical workflows. Coupling with high-resolution mass spectrometry, multidimensional separations, and micro-flow formats is expanding analytical capability while reducing solvent use. Analytical Quality by Design (AQbD), digital method modeling, and chemometric optimization tools are expected to play a larger role in UPLC method development. Green chromatography initiatives are also driving interest in shorter gradients, reduced solvent consumption, and environmentally safer mobile phases. Together, these developments suggest that UPLC will remain central to next-generation pharmaceutical analysis strategies.[35]

10. CONCLUSION AND SUMMARY

Ultra-Performance Liquid Chromatography has emerged as a major advancement in liquid chromatographic analysis by building upon the theoretical and practical foundation established by conventional HPLC. Through the use of sub-2 µm particle columns, high-pressure delivery systems, and low-dispersion instrument design, UPLC achieves faster separations, higher resolution, and improved sensitivity while reducing solvent consumption and analysis time. These performance advantages have made UPLC increasingly valuable for pharmaceutical dosage form analysis, particularly in assay determination, impurity profiling, stability-indicating studies, dissolution testing, and bioanalytical applications.

Method development in UPLC follows the same scientific principles as HPLC but requires tighter control of chromatographic variables and a more structured optimization strategy. Modern approaches such as Analytical Quality by Design and risk-based method development further strengthen robustness and lifecycle reliability. Validation expectations remain aligned with international regulatory guidelines, ensuring that UPLC methods meet requirements for specificity, accuracy, precision, linearity, sensitivity, and robustness before routine use.

Although challenges related to cost, method transfer, and system sensitivity exist, ongoing technological and methodological innovations are steadily addressing these limitations. Integration with advanced detection systems, automation, chemometric tools, and green analytical practices is expected to further expand the practical utility of UPLC. Overall, UPLC represents not a replacement but a high-performance evolution of HPLC, offering enhanced analytical capability while maintaining regulatory and theoretical continuity. Its continued adoption will play a significant role in improving efficiency, reliability, and scientific depth in pharmaceutical analytical laboratories.

11. REFERENCES

1. Swartz ME. Ultra performance liquid chromatography (UPLC): an introduction. J Liq Chromatogr Relat Technol, 2017; 40(5): 214-29.
2. Dong MW. Modern HPLC and UHPLC for practicing scientists, 2nd ed. Hoboken: Wiley, 2019.
3. Fekete S, Guillarme D. Current and future trends in UHPLC. Trends Anal Chem, 2018; 102: 1-12.
4. Guillarme D, Veuthey JL. UHPLC in pharmaceutical analysis. J Pharm Biomed Anal, 2019; 164: 708-22.
5. Fekete J, Fekete S, Ganzler K. Critical evaluation of fast liquid chromatography. J Pharm Biomed Anal, 2017; 135: 113-25.
6. ICH. Q2(R1) Validation of analytical procedures: text and methodology. Geneva, 2016.
7. Kazakevich Y, Lobrutto R. HPLC for pharmaceutical scientists. Hoboken: Wiley, 2017.
8. Meyer VR. Practical high-performance liquid chromatography. 5th ed. Chichester: Wiley, 2017.
9. Ahuja S, Dong MW. Handbook of pharmaceutical analysis by HPLC. Amsterdam: Elsevier, 2018.
10. FDA. Analytical procedures and methods validation guidance. Silver Spring, 2018.
11. Desmet G, Gzil P. Small particle separations in liquid chromatography. J Chromatogr A, 2017; 1480: 2-14.
12. Neue UD, Mazzeo JR. Advances in column technology for UHPLC. Anal Chem, 2018; 90(1): 34-50.
13. Gritti F, Guiochon G. Mass transfer kinetics in modern LC columns. J Chromatogr A, 2017; 1498: 1-15.
14. Fekete S, Beck A, Veuthey JL, Guillarme D. Method transfer from HPLC to UHPLC. J Pharm Biomed Anal, 2017; 137: 38-47.
15. Guillarme D, Veuthey JL. Instrumental requirements for UHPLC. Trends Anal Chem, 2019; 110: 1-9.
16. Nováková L, Vlčková H. Advances in UHPLC-MS. Anal Chim Acta, 2018; 1026: 1–15.
17. Sandra P, Sandra K. Column technologies in UHPLC. LC GC Europe, 2018; 31(6): 320-28.
18. Hopfgartner G. LC-MS in pharmaceutical analysis. Anal Bioanal Chem, 2019; 411: 5955-67.
19. Dolan JW. LC method development fundamentals. LC GC North Am, 2018; 36(10): 784-91.
20. Snyder LR, Dolan JW. Gradient elution optimization. J Chromatogr A, 2017; 1489: 3-14.
21. Rozet E, Lebrun P, Hubert P. QbD approach for analytical method development. Trends Anal Chem, 2018; 107: 281-92.
22. Vogeser M, Seger C. Sample preparation in pharmaceutical LC. Clin Biochem, 2017; 50: 123-30.
23. Patel KG, Shah PM. Development of UPLC methods for dosage forms. J Pharm Anal, 2019; 9(4): 245-52.
24. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Stability indicating methods review. J Pharm Anal, 2016; 6(2): 89-98.
25. Singh S, Junwal M. Forced degradation studies in drug development. J Pharm Biomed Anal, 2018; 147: 590-611.
26. Bakshi M, Singh S. Development of validated stability methods. J Pharm Biomed Anal, 2017; 136: 104-15.
27. Ermer J, Nethercote P. Method validation in pharmaceutical analysis. J Pharm Biomed Anal, 2018; 152: 3-10.
28. Taverniers I, De Loose M, Van Bockstaele E. Validation concepts. Trends Anal Chem, 2017; 87: 37-49.
29. Shrivastava A, Gupta V. Methods for LOD and LOQ estimation. Chron Young Sci, 2016; 7(1): 1-7.
30. Vander Heyden Y. Robustness testing in LC. J Chromatogr A, 2017; 1490: 1-10.
31. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q14 Analytical Procedure Development. Geneva: ICH, 2023.
32. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Q2(R2) Validation of Analytical Procedures. Geneva: ICH, 2023.
33. Vogt FG, Kord AS. Development of quality-by-design analytical methods. J Pharm Biomed Anal, 2021; 193: 113681.
34. Borman P. Analytical procedure lifecycle management under ICH Q14. Eur Pharm Rev, 2024, 29(2): 12–18.
35. Inoue K, Samukawa T, Hiyama Y. Overview of ICH Q2(R2) and Q14: modernisation of analytical validation and development. Pharm Med Device Regul Sci, 2023; 54(12): 1023–1032.